Rocklage Scott M's Form 4 filing
Pear Therapeutics, Inc.PEAR · filed Apr 12, 2023
- Accession no.
- 0001209191-23-024105
- Filed
- Apr 12, 2023, 4:51 PM ET
- Trade date
- Apr 10, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.99M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rocklage Scott MCIK 0001219014 | 10% Owner |
| Diekman John DCIK 0001240357 | 10% Owner |
| 5AM Partners IV, LLCCIK 0001589314 | 10% Owner |
| 5AM Ventures IV, L.P.CIK 0001589315 | 10% Owner |
| 5AM Co-Investors IV, L.P.CIK 0001593361 | 10% Owner |
| Schwab Andrew J.CIK 0001598549 | 10% Owner |
| 5AM Opportunities I, L.P.CIK 0001753000 | 10% Owner |
| 5AM Opportunities I (GP), LLCCIK 0001790778 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2023 | Class A Common Stock | SSaleDisposed | −12,836,489 | $0.12F1 | −$1,540,378.68 | 0 | Indirect | |
| Apr 10, 2023 | Class A Common Stock | SSaleDisposed | −534,855 | $0.12F1 | −$64,182.6 | 0 | Indirect | |
| Apr 10, 2023 | Class A Common Stock | SSaleDisposed | −3,172,769 | $0.12F1 | −$380,732.28 | 200,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 3 transactions in Table I.